

belumosudil mesylate (REZUROCK)

Diagnoses Considered for Coverage:

- Graft versus host disease (GVHD)

Coverage Criteria:

For diagnosis of graft versus host disease (GVHD):

- Inadequate response to at least two prior systemic therapies for GVHD (i.e. systemic corticosteroids, immunosuppressants), **and**
- Dose does not exceed 200 mg once daily.

Coverage Duration: one year

Effective Date: 11/02/2023